JP2019530699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530699A5 JP2019530699A5 JP2019518406A JP2019518406A JP2019530699A5 JP 2019530699 A5 JP2019530699 A5 JP 2019530699A5 JP 2019518406 A JP2019518406 A JP 2019518406A JP 2019518406 A JP2019518406 A JP 2019518406A JP 2019530699 A5 JP2019530699 A5 JP 2019530699A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- substituted
- bicyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 80
- 229910052799 carbon Inorganic materials 0.000 claims 65
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 63
- 125000003545 alkoxy group Chemical group 0.000 claims 63
- 125000002950 monocyclic group Chemical group 0.000 claims 60
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 48
- 125000000623 heterocyclic group Chemical group 0.000 claims 45
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000005842 heteroatom Chemical group 0.000 claims 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405309P | 2016-10-07 | 2016-10-07 | |
| US62/405,309 | 2016-10-07 | ||
| PCT/US2017/054710 WO2018067432A1 (en) | 2016-10-07 | 2017-10-02 | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530699A JP2019530699A (ja) | 2019-10-24 |
| JP2019530699A5 true JP2019530699A5 (enExample) | 2020-11-12 |
| JP7097875B2 JP7097875B2 (ja) | 2022-07-08 |
Family
ID=60117794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518406A Active JP7097875B2 (ja) | 2016-10-07 | 2017-10-02 | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10836770B2 (enExample) |
| EP (1) | EP3523305B1 (enExample) |
| JP (1) | JP7097875B2 (enExample) |
| KR (1) | KR102531036B1 (enExample) |
| CN (1) | CN110036015B (enExample) |
| ES (1) | ES2902995T3 (enExample) |
| MA (1) | MA46453A (enExample) |
| WO (1) | WO2018067432A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| JP7179161B2 (ja) | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| EP3849969B1 (en) * | 2018-09-13 | 2023-04-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| JP2022509019A (ja) | 2018-11-05 | 2022-01-20 | シンジェンタ パーティシペーションズ アーゲー | 殺有害生物的に活性なアゾール－アミド化合物 |
| AR117177A1 (es) | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| CN113348021B (zh) * | 2019-01-23 | 2025-07-11 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| ES2953140T3 (es) | 2019-03-08 | 2023-11-08 | Syngenta Crop Protection Ag | Compuestos de azol-amida activos de manera plaguicida |
| US12552766B2 (en) | 2019-03-20 | 2026-02-17 | Syngenta Crop Protection Ag | Pesticidally active azole amide compounds |
| JP2022525809A (ja) | 2019-03-22 | 2022-05-19 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺虫剤としてのｎ－［１－（５－ブロモ－２－ピリミジン－２－イル－１，２，４－トリアゾール－３－イル）エチル］－２－シクロプロピル－６－（トリフルオロメチル）ピリジン－４－カルボキサミド誘導体及び関連化合物 |
| SG11202112043PA (en) | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| TWI810520B (zh) | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
| CN115052660B (zh) | 2020-02-12 | 2024-01-09 | 伊莱利利公司 | 取代的7-(甲氨基)吡唑并[1,5-a]嘧啶-3-甲酰胺衍生物 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN115916207A (zh) * | 2020-08-20 | 2023-04-04 | 轶诺(浙江)药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| EP4214215A1 (en) * | 2020-09-16 | 2023-07-26 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| CA3213816A1 (en) | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CN116655636A (zh) * | 2022-02-17 | 2023-08-29 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| JP6073343B2 (ja) | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
-
2017
- 2017-10-02 ES ES17784774T patent/ES2902995T3/es active Active
- 2017-10-02 MA MA046453A patent/MA46453A/fr unknown
- 2017-10-02 WO PCT/US2017/054710 patent/WO2018067432A1/en not_active Ceased
- 2017-10-02 EP EP17784774.6A patent/EP3523305B1/en active Active
- 2017-10-02 JP JP2019518406A patent/JP7097875B2/ja active Active
- 2017-10-02 KR KR1020197012692A patent/KR102531036B1/ko active Active
- 2017-10-02 US US16/339,744 patent/US10836770B2/en active Active
- 2017-10-02 CN CN201780075174.6A patent/CN110036015B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530699A5 (enExample) | ||
| JP2019501125A5 (enExample) | ||
| JP2020502268A5 (enExample) | ||
| AR054084A1 (es) | Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen | |
| RU2016110755A (ru) | Соединение, ингибирующее активности киназ ВТК и/или JAK3 | |
| JP2019532092A5 (enExample) | ||
| JP2020510091A5 (enExample) | ||
| RU2016143333A (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| JP2016514159A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| JP2014501766A5 (enExample) | ||
| JP2018522879A5 (enExample) | ||
| JP2018522033A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2020508327A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2016518385A5 (enExample) | ||
| JP2013533883A5 (enExample) | ||
| JP2015501327A5 (enExample) | ||
| JP2017506666A5 (enExample) | ||
| EA201492250A1 (ru) | Гетероциклическое соединение | |
| JP2017501237A5 (enExample) | ||
| JP2019501927A5 (enExample) | ||
| JP2019535723A5 (enExample) |